Norgestimate drug data and news

Norgestimate drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.

Generic name

Norgestimate

Brand Names/Synonyms

Dexnorgestrel Acetime; Ethinylestradiol and Norgestimate; NORGESTIMATE; Norgestimate; Norgestimate [Usan:Ban:Inn]; Norgestimate and Ethinylestradiol; Norgestimato [Inn-Spanish]; Norgestimatum [Inn-Latin]; Ortho Cyclen-21; Ortho Cyclen-28; Ortho Tri-Cyclen; Ortho-Prefest

Indication

For the prevention of pregnancy

Sponsored links

Description

Not Available

Pharmacology

Norgestimate is used as a female contraceptive. Norgestimate is a progestin or a synthetic form of the naturally occurring female sex hormone, progesterone. In a woman's normal menstrual cycle, an egg matures and is released from the ovaries (ovulation). The ovary then produces progesterone, preventing the release of further eggs and priming the lining of the womb for a possible pregnancy. If pregnancy occurs, progesterone levels in the body remain high, maintaining the womb lining. If pregnancy does not occur, progesterone levels in the body fall, resulting in a menstrual period. Norgestimate tricks the body processes into thinking that ovulation has already occurred, by maintaining high levels of the synthetic progesterone. This prevents the release of eggs from the ovaries.

Mechanism Of Action

Norgestimate binds to androgen and progestogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like Norgestimate will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge.

Norgestimate News
(When available)

Transdermal Patches: An Innovative Drug Delivery System That Has ... 07 Mar 2006
...clots] associated with this new transdermal combination hormonal contraceptive containing the new molecular entity progestin norelgestromin (17d-norgestimate ... - Newsinferno.com,

Results of Two Epidemiological Studies Provide Important New ... Feb 16, 2006
...to evaluate the combined risk of heart attack and stroke in first-time users of ORTHO EVRA(R) compared with first-time users of a norgestimate-containing oral ... - International News Service,

Evidence on Ortho Evra Patch Thrombosis Risk Is Contradictory Feb 17, 2006
...transdermal system) had about a two-fold increased risk for non-fatal venous thromboembolic events compared with women who took a norgestimate-containing oral ... - MedPage Today,

Conflicting Results in Ortho Tests Feb 17, 2006
...however, they had an about a two-fold increased risk for non-fatal venous thromboembolic events compared with women who took a norgestimate-containing oral ... - International News Service,

FDA Official Calls Results of Ortho Evra Birth Control Patch ... Feb 21, 2006
...attack, stroke and blood clots in the legs or lungs in women using Ortho Evra and women taking oral contraceptive pills containing norgestimate and estrogen. ... - Kaiser network.org,

No stroke, heart attack hike in Ortho test Feb 17, 2006
...to evaluate the combined risk of heart attack and stroke in first-time users of Ortho Evra, compared with first-time users of a norgestimate-containing oral ... - United Press International

Dosage Forms

Tablet

Drug_Category

Contraceptives; ATC:G03AA11

Absorption

Not Available

Interactions

Interactions for Norgestimate: Reduced efficacy and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin. A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72. A possible interaction has been suggested with hormonal contraceptives and the herbal supplement St. John's Wort based on some reports of oral contraceptive users experiencing breakthrough bleeding shortly after starting St. John's Wort. Pregnancies have been reported by users of combined hormonal contraceptives who also used some form of St. John's Wort. Healthcare prescribers are advised to consult the package inserts of medication administered concomitantly with oral contraceptives.

Toxicity

Not Available

Organisms Affected

Humans and other mammals

Chemical IUPAC Name

(13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl) acetate

Chemical Formula

C23H31NO3

Molecular Weight

369.497 g/mol

Smiles String

CCC12CCC3C(C1CCC2(C#C)OC(=O)C)CCC4=CC(=NO)CCC34

Melting Point

216 °C

Water Solubility

Not Available

State

Solid

LogP/Hphobicity

3.944

Isoelectric Point

Not Available

Biotransformation

GI tract/Hepatic

Half Life

12-30 hours

Protein Binding [%]

Not Available

RxList Link

RXlist

Sponsored links

Drug Reference

http://www.rxlist.com/cgi/generic/norgestimest.htm

Drug Type

Approved Drug

Accession No

APRD00569

CAS Registry Number

35189-28-7

KEGG Compound ID

Not Available

PubChem ID

SID:178495

PharmGKB ID

PA450655

SwissProt ID

Not Available

GenBank ID

Not Available

Drug ID Number [DIN]

Not Available